ES2187520T3 - Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina. - Google Patents

Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina.

Info

Publication number
ES2187520T3
ES2187520T3 ES94910445T ES94910445T ES2187520T3 ES 2187520 T3 ES2187520 T3 ES 2187520T3 ES 94910445 T ES94910445 T ES 94910445T ES 94910445 T ES94910445 T ES 94910445T ES 2187520 T3 ES2187520 T3 ES 2187520T3
Authority
ES
Spain
Prior art keywords
pct
cytoquine
muramil
peptide
association
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94910445T
Other languages
English (en)
Inventor
Louis Chedid
Georges Bahr
Pierre Lefrancier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vacsyn SA
Original Assignee
Vacsyn SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9303230A external-priority patent/FR2702659B1/fr
Priority claimed from FR9303787A external-priority patent/FR2703251B3/fr
Application filed by Vacsyn SA filed Critical Vacsyn SA
Application granted granted Critical
Publication of ES2187520T3 publication Critical patent/ES2187520T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION QUE ASOCIA, PARA SU APLICACION EN TERAPIA HUMANA, AL MENOS UNA CITOQUINA NATURAL O RECOMBINANTE, PREFERENTEMENTE HUMANA, CON LA MENOS UN MURAMILPEPTIDO ELEGIDO ENTRE LOS QUE, CUANDO SON ADMINISTRADOS "IN VIVO" EN ASOCIACION CON UN INTERFERON, INDUCEN TAMBIEN LA PRODUCCION INCREMENTADA IN VIVO DE UN ANTAGONISTA IL-1 RA DEL RECEPTOR DE LA INTERLEUQUINA I Y, PREFERENTEMENTE, NO INDUCEN UN CRECIMIENTO DE LAS CITOQUINAS IL-1, TNF Y IL-8. SE PUEDE UTILIZAR PARA TERAPIAS ANTIVIRALES, ANTITUMORALES Y/O PARA FAVORECER UNA RECONSTITUCION DEL SISTEMA HEMATOPOIETICO, PARTICULARMENTE EN PERSONAS CUYO SISTEMA INMUNITARIO ES O SE HA VUELTO DEFICIENTE.
ES94910445T 1993-03-19 1994-03-21 Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina. Expired - Lifetime ES2187520T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9303230A FR2702659B1 (fr) 1993-03-19 1993-03-19 Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine.
FR9303787A FR2703251B3 (fr) 1993-03-31 1993-03-31 Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine .

Publications (1)

Publication Number Publication Date
ES2187520T3 true ES2187520T3 (es) 2003-06-16

Family

ID=26230187

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94910445T Expired - Lifetime ES2187520T3 (es) 1993-03-19 1994-03-21 Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina.

Country Status (11)

Country Link
US (1) US5932208A (es)
EP (1) EP0689449B1 (es)
JP (1) JP3723206B2 (es)
AT (1) ATE226828T1 (es)
AU (1) AU6285694A (es)
CA (1) CA2157758A1 (es)
DE (1) DE69431620T2 (es)
DK (1) DK0689449T3 (es)
ES (1) ES2187520T3 (es)
PT (1) PT689449E (es)
WO (1) WO1994021275A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6267968B1 (en) * 1995-04-07 2001-07-31 Vacsyn S.A. MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same
EP2002846B1 (en) 1996-12-06 2017-01-25 Amgen Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7033594B2 (en) 2000-03-31 2006-04-25 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
FR2809106A1 (fr) * 2000-05-17 2001-11-23 Istac Polypeptide ro/ssa-like et ses fragments et polynucleotides codant lesdits polypeptides et applications therapeutiques
US6886964B2 (en) * 2001-06-26 2005-05-03 Allan Gardiner Illuminator with filter array and bandwidth controller
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
ES2338305T3 (es) * 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
US20030097409A1 (en) * 2001-10-05 2003-05-22 Hungchou Tsai Systems and methods for securing computers
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
JP2006517191A (ja) * 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
US7546638B2 (en) * 2003-03-18 2009-06-09 Symantec Corporation Automated identification and clean-up of malicious computer code
DK1708690T3 (en) * 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
EP2436379A1 (en) * 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
WO2007092299A2 (en) * 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CN101918018B (zh) 2007-11-14 2012-12-05 再生医药有限公司 使用白介素-1受体拮抗剂作为骨髓保护剂的方法
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
IL83350A0 (en) * 1986-08-13 1987-12-31 Takeda Chemical Industries Ltd Pharmaceutical compositions comprising interleukin and intterferon active substances
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination

Also Published As

Publication number Publication date
WO1994021275A1 (fr) 1994-09-29
JPH08511235A (ja) 1996-11-26
CA2157758A1 (en) 1994-09-29
US5932208A (en) 1999-08-03
EP0689449B1 (fr) 2002-10-30
EP0689449A1 (fr) 1996-01-03
JP3723206B2 (ja) 2005-12-07
DE69431620T2 (de) 2003-07-03
ATE226828T1 (de) 2002-11-15
AU6285694A (en) 1994-10-11
DE69431620D1 (de) 2002-12-05
PT689449E (pt) 2003-03-31
DK0689449T3 (da) 2003-03-03

Similar Documents

Publication Publication Date Title
ES2187520T3 (es) Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina.
Lacey et al. IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1, 25 dihydroxyvitamin D3.
AR034049A1 (es) Uso de anticuerpos anti-tnf como farmacos en el tratamiento de trastornos septicos de pacientes anemicos
BR9910505A (pt) Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
BRPI0317064B8 (pt) composições compreendendo células dendríticas parcialmente amadurecidas in vitro
NO965621L (no) Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
DK0613499T3 (da) Humame IT-4-mutantproteiner
Yeh et al. Changes in serum tumour necrosis factor-α in burned patients
BRPI0415290A (pt) uso terapêutico de variantes de quimiocina
CA2388338A1 (en) Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
ATE159172T1 (de) Peptide und deren verwendung
IT1276555B1 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni
DK0742720T3 (da) Co-indgivelse af interleukin-3-mutantpolypeptider med CSF'er til produktion af hæmatopoietiske celler med multi-afstamning
DE60233654D1 (de) Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung
Femandez‐Botran et al. Control of the production of soluble interleukin‐4 receptors: implications in immunoregulation
DE69836278D1 (de) Allele formen von menschlichem stat3
AU6942896A (en) Use of muteins of wild-type cytokines as immunogens
IT8821878V0 (it) Dispositivo migliorato per la regolazione dell'inclinazione dello schienale e/o del sedile di seggiole in genere, in particolare per ufficio.
Rouse Use of heat-pressed leucite reinforced porcelain in “difficult” veneer cases: A clinical report
Yasuji et al. Spontaneous release of B lymphocyte-enhancing factors for growth and differentiation by YH-1 cells in serum-free culture media-Identification of interleukin 1 activities.
Bajetto et al. IL-1 receptor antagonist production by B and T lymphocytes
Barak et al. The M20 IL-1 inhibitor is distinct from the IL-1ra
David Re: Depression as a Risk Factor for Cancer: Renewing a Debate on the Psychobiology of Disease
Penninx et al. Response: Re: Depression as a Risk Factor for Cancer: Renewing a Debate on the Psychobiology of Disease